Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer

Jan Craig Buckner, James N. Ingle, Lloyd K. Everson, Judith R. O'Fallon, Stephen A. Cullinan, David L. Ahmann, James E. Krook, Delano M. Pfeifle

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29% (47 responses in 161 patients) and to salvage chemotherapy was 28% (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25%). Response rates were similar for patients who began salvage CFP ≤12 months or >12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.

Original languageEnglish (US)
Pages (from-to)135-142
Number of pages8
JournalBreast Cancer Research and Treatment
Volume13
Issue number2
DOIs
StatePublished - Mar 1989

Fingerprint

Salvage Therapy
Mastectomy
Adjuvant Chemotherapy
Prednisone
Fluorouracil
Cyclophosphamide
Breast Neoplasms
Drug Therapy
Retreatment
Tamoxifen
Estrogen Receptors
Recurrence
Therapeutics
Population

Keywords

  • adjuvant chemotherapy
  • metastatic breast cancer
  • salvage chemotherapy
  • salvage hormone therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. / Buckner, Jan Craig; Ingle, James N.; Everson, Lloyd K.; O'Fallon, Judith R.; Cullinan, Stephen A.; Ahmann, David L.; Krook, James E.; Pfeifle, Delano M.

In: Breast Cancer Research and Treatment, Vol. 13, No. 2, 03.1989, p. 135-142.

Research output: Contribution to journalArticle

Buckner, Jan Craig ; Ingle, James N. ; Everson, Lloyd K. ; O'Fallon, Judith R. ; Cullinan, Stephen A. ; Ahmann, David L. ; Krook, James E. ; Pfeifle, Delano M. / Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. In: Breast Cancer Research and Treatment. 1989 ; Vol. 13, No. 2. pp. 135-142.
@article{c12d4242b68a4282a4b68301b41520e5,
title = "Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer",
abstract = "We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29{\%} (47 responses in 161 patients) and to salvage chemotherapy was 28{\%} (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25{\%}). Response rates were similar for patients who began salvage CFP ≤12 months or >12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.",
keywords = "adjuvant chemotherapy, metastatic breast cancer, salvage chemotherapy, salvage hormone therapy",
author = "Buckner, {Jan Craig} and Ingle, {James N.} and Everson, {Lloyd K.} and O'Fallon, {Judith R.} and Cullinan, {Stephen A.} and Ahmann, {David L.} and Krook, {James E.} and Pfeifle, {Delano M.}",
year = "1989",
month = "3",
doi = "10.1007/BF01806525",
language = "English (US)",
volume = "13",
pages = "135--142",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer

AU - Buckner, Jan Craig

AU - Ingle, James N.

AU - Everson, Lloyd K.

AU - O'Fallon, Judith R.

AU - Cullinan, Stephen A.

AU - Ahmann, David L.

AU - Krook, James E.

AU - Pfeifle, Delano M.

PY - 1989/3

Y1 - 1989/3

N2 - We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29% (47 responses in 161 patients) and to salvage chemotherapy was 28% (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25%). Response rates were similar for patients who began salvage CFP ≤12 months or >12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.

AB - We have evaluated the results of salvage systemic therapy in 257 patients with breast cancer recurrent after surgical adjuvant treatment with cyclophosphamide, fluorouracil, and prednisone (CFP) with or without tamoxifen. The overall objective response rate to salvage hormonal therapy was 29% (47 responses in 161 patients) and to salvage chemotherapy was 28% (43 responses in 156 patients). Response rates to salvage chemotherapy were similar whether or not prior salvage hormonal therapy or local modalities had been administered. Retreatment with CFP as a salvage chemotherapy yielded responses in 11 of 44 patients (25%). Response rates were similar for patients who began salvage CFP ≤12 months or >12 months after completion of adjuvant CFP. We conclude that when this unselected population of patients failing adjuvant CFP is considered, 1) response rates to salvage chemotherapy were low regardless of whether or not prior salvage hormonal or local therapies were given, 2) repeating adjuvant chemotherapy (CFP) following relapse produced a low response rate, and 3) response rates to salvage hormonal therapy were low, but on the order of those observed in patients with advanced disease unselected by estrogen receptor status who are treated with first line hormonal maneuvers.

KW - adjuvant chemotherapy

KW - metastatic breast cancer

KW - salvage chemotherapy

KW - salvage hormone therapy

UR - http://www.scopus.com/inward/record.url?scp=0024597830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024597830&partnerID=8YFLogxK

U2 - 10.1007/BF01806525

DO - 10.1007/BF01806525

M3 - Article

C2 - 2659104

AN - SCOPUS:0024597830

VL - 13

SP - 135

EP - 142

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -